Skip to main content
SpringerLink
Log in

Apparent Mineralocorticoid Excess

  • Reference work entry
  • First Online:
Hydro Saline Metabolism

Part of the book series: Endocrinology ((ENDOCR))

  • 149 Accesses

Abstract

Context: Arterial hypertension (AHT) is one of the most frequent pathologies in the general population. Subtypes of essential hypertension characterized by low-renin levels allowed the identification of two different clinical entities: aldosterone-mediated mineralocorticoid receptor (MR) activation and cortisol-mediated MR activation. The spectrum of cortisol-mediated MR activation includes the classic apparent mineralocorticoid excess (AME) to milder (nonclassic, NC) forms of AME, the latter with a much higher prevalence than classic AME but different phenotype and genotype. AME is a rare autosomal recessive disorder caused by the presence of a severe deficiency of 11βHSD2 activity, mainly due to a multiple pathogenic variant in the HSD11B2 gene. The clinical features are childhood onset hypertension, hypokalemia, and alkalosis with low plasma renin, but unlike primary aldosteronism (PA), AME displays low aldosterone levels in the presence of a high serum or urinary cortisol/cortisone (F/E) ratio. NC-AME is mainly related to partial 11βHSD2 deficiency associated with genetic variations and epigenetic modifications (first hit) and potential additive actions of endogenous or exogenous inhibitors (i.e., glycyrrhetinic acid-like factors (GALFS)) and other factors (i.e., age, high sodium intake) (second hit). Subjects with NC-AME are characterized by high F/E ratio and low E levels, normal and elevated blood pressure, low-renin and increased urinary potassium excretion and microalbuminuria. Subjects with the AME condition should benefit with low-sodium diet, potassium supplementation and monotherapy with MR antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 379.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdellatif M. The role of microRNA-133 in cardiac hypertrophy uncovered. Circ Res. 2010;106:16–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Adlin EV, Braitman LE, Vasan RS. Bimodal aldosterone distribution in low-renin hypertension. Am J Hypertens. 2013;26:1076–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest. 2004;114:1146–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alikhani-Koupaei R, Fouladkou F, Fustier P, et al. Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J. 2007;21:3618–28.

    Article  CAS  PubMed  Google Scholar 

  • Angelini A, Li Z, Mericskay M, Decaux JF. Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/microRNA-133a axis. PLoS One. 2015;10:e0139858.

    Article  PubMed  PubMed Central  Google Scholar 

  • Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268–75.

    Article  CAS  PubMed  Google Scholar 

  • Arriza JL, Simerly RB, Swanson LW, Evans RM. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron. 1988;1:887–900.

    Article  CAS  PubMed  Google Scholar 

  • Atanasov AG, Ignatova ID, Nashev LG, et al. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol. 2007;18:1262–70.

    Article  CAS  PubMed  Google Scholar 

  • Athimulam S, Lazik N, Bancos I. Low-renin hypertension. Endocrinol Metab Clin N Am. 2019;48:701–15.

    Article  Google Scholar 

  • Azizi M, Rossignol P, Hulot JS. Emerging drug classes and their potential use in hypertension. Hypertension. 2019;74:1075–83.

    Article  CAS  PubMed  Google Scholar 

  • Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455:64–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bailey MA, Craigie E, Livingstone DEW, et al. Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure. Hypertension. 2011;57:515–20.

    Article  CAS  PubMed  Google Scholar 

  • Baker MA, Wang F, Liu Y, et al. MiR-192-5p in the kidney protects against the development of hypertension. Hypertension. 2019;73:399–406.

    Article  CAS  PubMed  Google Scholar 

  • Bakhiya N, Monien B, Frank H, Seidel A, Glatt H. Renal organic anion transporters OAT1 and OAT3 mediate the cellular accumulation of 5-sulfooxymethylfurfural, a reactive, nephrotoxic metabolite of the Maillard product 5-hydroxymethylfurfural. Biochem Pharmacol. 2009;78:414–9.

    Article  CAS  PubMed  Google Scholar 

  • Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.

    Article  CAS  PubMed  Google Scholar 

  • Ball JP, Syed M, Maranon RO, et al. Role and regulation of microRNAs in aldosterone-mediated cardiac injury and dysfunction in male rats. Endocrinology. 2017;158:1859–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barros ER, Carvajal CA. Urinary exosomes and their cargo: potential biomarkers for mineralocorticoid arterial hypertension? Front Endocrinol. 2017;8:230.

    Article  Google Scholar 

  • Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  • Batkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep. 2012;14:79–87.

    Article  CAS  PubMed  Google Scholar 

  • Baudrand R, Vaidya A. The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int J Mol Sci. 2018a;19:pii: E546.

    Article  Google Scholar 

  • Baudrand R, Vaidya A. The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int J Mol Sci. 2018b;19:546.

    Article  PubMed  PubMed Central  Google Scholar 

  • Baudrand R, Guarda FJ, Fardella C, et al. Continuum of renin-independent aldosteronism in normotension. Hypertension. 2017;69:950–6.

    Article  CAS  PubMed  Google Scholar 

  • Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Best R, Walker BR. Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11beta-hydroxysteroid dehydrogenase in vivo. Clin Endocrinol. 1997;47:231–6.

    Article  CAS  Google Scholar 

  • Bokkenheuser VD, Winter J, Honour JW, Shackleton CH. Reduction of aldosterone by anaerobic bacteria: origin of urinary 21-deoxy metabolites in man. J Steroid Biochem. 1979;11:1145–9.

    Article  CAS  PubMed  Google Scholar 

  • Botero-Velez M, Curtis JJ, Warnock DG. Brief report. Liddle’s syndrome revisited – a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994;330:178–81.

    Article  CAS  PubMed  Google Scholar 

  • Brand E, Kato N, Chatelain N, et al. Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. J Hypertens. 1998;16:1627–33.

    Article  CAS  PubMed  Google Scholar 

  • Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med. 2017;167:630–41.

    Article  PubMed  PubMed Central  Google Scholar 

  • Butterworth MB. MicroRNAs and the regulation of aldosterone signaling in the kidney. Am J Physiol Cell Physiol. 2015;308:C521–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cabreiro F, Picot CR, Friguet B, Petropoulos I. Methionine sulfoxide reductases: relevance to aging and protection against oxidative stress. Ann N Y Acad Sci. 2006;1067:37–44.

    Article  CAS  PubMed  Google Scholar 

  • Campino C, Carvajal CA, Cornejo J, et al. 11beta-Hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension. Endocrine. 2010;37:106–14.

    Article  CAS  PubMed  Google Scholar 

  • Campino C, Quinteros H, Owen GI, et al. 11beta-hydroxysteroid dehydrogenase type 2 polymorphisms and activity in a Chilean essential hypertensive and normotensive cohort. Am J Hypertens. 2012;25:597–603.

    Article  CAS  PubMed  Google Scholar 

  • Campino C, Martinez-Aguayo A, Baudrand R, et al. Age-related changes in 11beta-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects. Am J Hypertens. 2013;26:481–7.

    Article  CAS  PubMed  Google Scholar 

  • Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1:98–110.

    PubMed  Google Scholar 

  • Canessa CM, Schild L, Buell G, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature. 1994;367:463–7.

    Article  CAS  PubMed  Google Scholar 

  • Carvajal CA, Gonzalez AA, Romero DG, et al. Two homozygous mutations in the 11beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 2003;88:2501–7.

    Article  CAS  PubMed  Google Scholar 

  • Carvajal CA, Herrada AA, Castillo CR, et al. Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J Endocrinol Invest. 2009;32:759–65.

    Article  CAS  PubMed  Google Scholar 

  • Carvajal CA, Tapia-Castillo A, Valdivia CP, et al. Serum cortisol and cortisone as potential biomarkers of partial 11beta-hydroxysteroid dehydrogenase type 2 deficiency. Am J Hypertens. 2018a;31:910–8.

    Article  CAS  PubMed  Google Scholar 

  • Carvajal CA, Tapia-Castillo A, Valdivia CP, et al. Serum cortisol and cortisone as potential biomarkers of partial 11β-hydroxysteroid dehydrogenase type-2 deficiency. Am J Hypertens. 2018b;31:hpy051.

    Article  Google Scholar 

  • Carvajal CA, Tapia-Castillo A, Vecchiola A, Baudrand R, Fardella CE. Classic and nonclassic apparent mineralocorticoid excess syndrome. J Clin Endocrinol Metab. 2020;105:dgz315.

    Article  PubMed  Google Scholar 

  • Castoldi G, Di Gioia CR, Bombardi C, et al. MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol. 2012;227:850–6.

    Article  CAS  PubMed  Google Scholar 

  • Charmandari E, Kino T. Novel causes of generalized glucocorticoid resistance. Horm Metab Res. 2007;39:445–50.

    Article  CAS  PubMed  Google Scholar 

  • Chen C, Lu C, Qian Y, et al. Urinary miR-21 as a potential biomarker of hypertensive kidney injury and fibrosis. Sci Rep. 2017;7:17737.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheng Y, Zeng Q, Han Q, Xia W. Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes. Protein Cell. 2019;10:295–9.

    Article  CAS  PubMed  Google Scholar 

  • Chin HJ, Song YR, Kim HS, et al. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci. 2009;24(Suppl):S50–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.

    Article  Google Scholar 

  • Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008;29:133–54.

    Article  CAS  PubMed  Google Scholar 

  • Cortes P, Fardella C, Oestreicher E, et al. Evidences for mineralocorticoid excess in essential hypertension. Rev Med Chile. 2000;128:955–61.

    CAS  PubMed  Google Scholar 

  • Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Craigie E, Evans LC, Mullins JJ, Bailey MA. Failure to downregulate the epithelial sodium channel causes salt sensitivity in Hsd11b2 heterozygote mice. Hypertension. 2012;60:684–90.

    Article  CAS  PubMed  Google Scholar 

  • Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568–77.

    Article  PubMed  Google Scholar 

  • Das S, Halushka MK. Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc Pathol. 2015;24:199–206.

    Article  CAS  PubMed  Google Scholar 

  • Deuchar GA, McLean D, Hadoke PWF, et al. 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe−/− mice. Endocrinology. 2011;152:236–46.

    Article  CAS  PubMed  Google Scholar 

  • Djousse L, Levy D, Cupples LA, Evans JC, D’Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol. 2001;87:1196–200. (A4, 7)

    Article  CAS  PubMed  Google Scholar 

  • Dostanic I, Paul RJ, Lorenz JN, Theriault S, Van Huysse JW, Lingrel JB. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol. 2005;288:H477–85.

    Article  CAS  PubMed  Google Scholar 

  • Egan BMZY, Axon RN, Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–50.

    Article  CAS  PubMed  Google Scholar 

  • Elvira-Matelot E, Zhou XO, Farman N, et al. Regulation of WNK1 expression by miR-192 and aldosterone. J Am Soc Nephrol. 2010;21:1724–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–62.

    Article  CAS  PubMed  Google Scholar 

  • Evans LC, Ivy JR, Wyrwoll C, et al. Conditional deletion of Hsd11b2 in the brain causes salt appetite and hypertension. Circulation. 2016;133:1360–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863–7.

    CAS  PubMed  Google Scholar 

  • Feraille E, Mordasini D, Gonin S, et al. Mechanism of control of Na,K-ATPase in principal cells of the mammalian collecting duct. Ann N Y Acad Sci. 2003;986:570–8.

    Article  CAS  PubMed  Google Scholar 

  • Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet. 2018;50:355–61.

    Article  CAS  PubMed  Google Scholar 

  • Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens. 2000;18:241–8.

    Article  CAS  PubMed  Google Scholar 

  • Ferrari P, Sansonnens A, Dick B, Frey FJ. In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension. 2001;38:1330–6.

    Article  CAS  PubMed  Google Scholar 

  • Flamant M, Placier S, Dubroca C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007;50:212–8.

    Article  CAS  PubMed  Google Scholar 

  • French KC, Antonyak MA, Cerione RA. Extracellular vesicle docking at the cellular port: extracellular vesicle binding and uptake. Semin Cell Dev Biol. 2017;67:48–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Friso S, Pizzolo F, Choi SW, et al. Epigenetic control of 11beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis. 2008;199:323–7.

    Article  CAS  PubMed  Google Scholar 

  • Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl Res. 2015;165:154–65.

    Article  CAS  PubMed  Google Scholar 

  • Funder JW. Is aldosterone bad for the heart? Trends Endocrinol Metab. 2004;15:139–42.

    Article  CAS  PubMed  Google Scholar 

  • Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Funder JW. Primary aldosteronism and salt. Pflügers Arch. 2015;467:587–94.

    Article  CAS  PubMed  Google Scholar 

  • Funder JW. Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol. 2017a;165:151–3.

    Article  CAS  PubMed  Google Scholar 

  • Funder JW. Aldosterone and mineralocorticoid receptors – physiology and pathophysiology. Int J Mol Sci. 2017b;18:1032.

    Article  PubMed  PubMed Central  Google Scholar 

  • Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol. 2016a;101:1889–916.

    Article  CAS  Google Scholar 

  • Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016b;101:1889–916.

    Article  CAS  PubMed  Google Scholar 

  • Ghazi L, Dudenbostel T, Hachem ME, et al. 11-Beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension. Am J Hypertens. 2017;30:518–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17:199–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gomez-Sanchez EP. Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule? Trends Endocrinol Metab. 2011;22:179–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gracia T, Wang X, Su Y, et al. Urinary exosomes contain microRNAs capable of paracrine modulation of tubular transporters in kidney. Sci Rep. 2017;7:40601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70:660–7.

    Article  CAS  PubMed  Google Scholar 

  • Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98:3971–3.

    Article  CAS  PubMed  Google Scholar 

  • Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – a review of the current literature. Horm Metab Res. 2012;44:157–62.

    Article  CAS  PubMed  Google Scholar 

  • Henschkowski J, Stuck AE, Frey BM, et al. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am J Hypertens. 2008;21:644–9.

    Article  CAS  PubMed  Google Scholar 

  • Herrada AA, Contreras FJ, Marini NP, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010;184:191–202.

    Article  CAS  PubMed  Google Scholar 

  • Honour J. The possible involvement of intestinal bacteria in steroidal hypertension. Endocrinology. 1982;110:285–7.

    Article  CAS  PubMed  Google Scholar 

  • Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–9.

    Article  PubMed  Google Scholar 

  • James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr. 2002;132:2361S–6S.

    Article  CAS  PubMed  Google Scholar 

  • Jimenez-Canino R, Lorenzo-Diaz F, Odermatt A, et al. 11beta-HSD2 SUMOylation modulates cortisol-induced mineralocorticoid receptor nuclear translocation independently of effects on transactivation. Endocrinology. 2017;158:4047–63.

    Article  CAS  PubMed  Google Scholar 

  • Kaplan JH. The sodium pump and hypertension: a physiological role for the cardiac glycoside binding site of the Na,K-ATPase. Proc Natl Acad Sci U S A. 2005;102:15723–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

    Article  PubMed  Google Scholar 

  • Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69–78.

    Article  CAS  PubMed  Google Scholar 

  • Kosicka K, Cymerys M, Majchrzak-Celinska A, Chuchracki M, Glowka FK. 11beta-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis. J Hum Hypertens. 2013;27:510–5.

    Article  CAS  PubMed  Google Scholar 

  • Koval SM, Snihurska IO, Yushko KO, et al. Circulating microRNA-133a in patients with arterial hypertension, hypertensive heart disease, and left ventricular diastolic dysfunction. Front Cardiovasc Med. 2020;7:104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krol J, Busskamp V, Markiewicz I, et al. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell. 2010;141:618–31.

    Article  CAS  PubMed  Google Scholar 

  • Krug AW, Ehrhart-Bornstein M. Adrenocortical dysfunction in obesity and the metabolic syndrome. Horm Metab Res. 2008;40:515–7.

    Article  CAS  PubMed  Google Scholar 

  • Kumagai A, Yano S, Otomo M. Study on the corticoid-like action of glycyrrhizine and the mechanism of its action. Endocrinol Jpn. 1957;4:17–27.

    Article  CAS  PubMed  Google Scholar 

  • Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35:716–24.

    Article  CAS  PubMed  Google Scholar 

  • Lana A, Alexander K, Castagna A, et al. Urinary metabolic signature of primary aldosteronism: gender and subtype-specific alterations. Proteomics Clin Appl. 2019;13:e1800049.

    Article  PubMed  Google Scholar 

  • Latif SA, Conca TJ, Morris DJ. The effects of the licorice derivative, glycyrrhetinic acid, on hepatic 3alpha- and 3beta-hydroxysteroid dehydrogenases and 5alpha- and 5beta-reductase pathways of metabolism of aldosterone in male rats. Steroids. 1990;55:52–8.

    Article  CAS  PubMed  Google Scholar 

  • Latif SA, Sheff MF, Ribeiro CE, Morris DJ. Selective inhibition of sheep kidney 11beta-hydroxysteroid dehydrogenase isoform 2 activity by 5alpha-reduced (but not 5beta) derivatives of adrenocorticosteroids. Steroids. 1997;62:230–7.

    Article  CAS  PubMed  Google Scholar 

  • Lavall D, Schuster P, Jacobs N, Kazakov A, Bohm M, Laufs U. Rac1 GTPase regulates 11beta hydroxysteroid dehydrogenase type 2 and fibrotic remodeling. J Biol Chem. 2017;292:7542–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lavery GG, Ronconi V, Draper N, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension. 2003;42:123–9.

    Article  CAS  PubMed  Google Scholar 

  • Leonard LJ, Townsend D, King RA. Function of dopachrome oxidoreductase and metal ions in dopachrome conversion in the eumelanin pathway. Biochemistry. 1988;27:6156–9.

    Article  CAS  PubMed  Google Scholar 

  • Leroy V, De Seigneux S, Agassiz V, et al. Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol. 2009;20:131–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li A, Li KX, Marui S, et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens. 1997;15:1397–402.

    Article  CAS  PubMed  Google Scholar 

  • Li A, Tedde R, Krozowski ZS, et al. Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am J Hum Genet. 1998;63:370–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lienhard D, Lauterburg M, Escher G, Frey FJ, Frey BM. High salt intake down-regulates colonic mineralocorticoid receptors, epithelial sodium channels and 11beta-hydroxysteroid dehydrogenase type 2. PLoS One. 2012;7:e37898.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lin X, Xu F, Cui RR, et al. Arterial calcification is regulated via an miR-204/DNMT3a regulatory circuit both in vitro and in female mice. Endocrinology. 2018;159:2905–16.

    Article  CAS  PubMed  Google Scholar 

  • Loirand G, Pacaud P. Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. Small GTPases. 2014;5:1–10.

    Article  PubMed  Google Scholar 

  • Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab. 1999;84:3745–9.

    CAS  PubMed  Google Scholar 

  • Ma X, Lian QQ, Dong Q, Ge RS. Environmental inhibitors of 11beta-hydroxysteroid dehydrogenase type 2. Toxicology. 2011;285:83–9.

    Article  CAS  PubMed  Google Scholar 

  • Ma F, Li Y, Jia L, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 2012;7:e35144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ma X, Lu C, Lv C, Wu C, Wang Q. The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J Diabetes Res. 2016;2016:6789402.

    Article  PubMed  PubMed Central  Google Scholar 

  • Manning JR, Bailey MA, Soares DC, Dunbar DR, Mullins JJ. In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence. Physiol Genomics. 2010;42:319–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mantero F, Tedde R, Opocher G, Dessi Fulgheri P, Arnaldi G, Ulick S. Apparent mineralocorticoid excess type II. Steroids. 1994;59:80–3.

    Article  CAS  PubMed  Google Scholar 

  • Marquez DF, Ruiz-Hurtado G, Segura J, Ruilope L. Microalbuminuria and cardiorenal risk: old and new evidence in different populations. F1000Res. 2019;8:1659.

    Article  CAS  Google Scholar 

  • Martinez ML, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006;47:117–22.

    Article  CAS  PubMed  Google Scholar 

  • Martinez-Aguayo A, Fardella C. Genetics of hypertensive syndrome. Horm Res. 2009;71:253–9.

    CAS  PubMed  Google Scholar 

  • Martinez-Martinez E, Buonafine M, Boukhalfa I, et al. Aldosterone target NGAL (neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NFkappaB pathway. Hypertension. 2017;70:1148–56.

    Article  CAS  PubMed  Google Scholar 

  • Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010;106:166–75.

    Article  CAS  PubMed  Google Scholar 

  • McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350:256–65.

    Article  CAS  PubMed  Google Scholar 

  • Michael A, Bajracharya SD, Yuen PS, et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010;16:34–8.

    Article  CAS  PubMed  Google Scholar 

  • Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.

    Article  CAS  PubMed  Google Scholar 

  • Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control. Circulation. 2016;134:441–50.

    Article  PubMed  PubMed Central  Google Scholar 

  • Min X, Lee BH, Cobb MH, Goldsmith EJ. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure. 2004;12:1303–11.

    Article  CAS  PubMed  Google Scholar 

  • Mladinov D, Liu Y, Mattson DL, Liang M. MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase beta1. Nucleic Acids Res. 2013;41:1273–83.

    Article  CAS  PubMed  Google Scholar 

  • Monaghan PJ, Keevil BG, Stewart PM, Trainer PJ. Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J Clin Endocrinol Metab. 2014;99:4434–7.

    Article  CAS  PubMed  Google Scholar 

  • Monien BH, Engst W, Barknowitz G, Seidel A, Glatt H. Mutagenicity of 5-hydroxymethylfurfural in V79 cells expressing human SULT1A1: identification and mass spectrometric quantification of DNA adducts formed. Chem Res Toxicol. 2012;25:1484–92.

    Article  CAS  PubMed  Google Scholar 

  • Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–20.

    Article  PubMed  Google Scholar 

  • Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol. 2006;17:3176–84.

    Article  CAS  PubMed  Google Scholar 

  • Morris DJ, Semafuko WE, Latif SA, Vogel B, Grimes CA, Sheff MF. Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension. 1992;20:356–60.

    Article  CAS  PubMed  Google Scholar 

  • Morris DJ, Latif SA, Hardy MP, Brem AS. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol. 2007;104:161–8.

    Article  CAS  PubMed  Google Scholar 

  • Mosso L, Fardella C, Montero J, et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Rev Med Chile. 1999;127:800–6.

    CAS  PubMed  Google Scholar 

  • Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–5.

    Article  CAS  PubMed  Google Scholar 

  • Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045–50.

    Article  CAS  PubMed  Google Scholar 

  • Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9:104–12.

    Article  CAS  PubMed  Google Scholar 

  • Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394–9.

    Article  CAS  PubMed  Google Scholar 

  • Muñoz-Durango N, Barake MF, Letelier NA, Campino C, Fardella CE, Kalergis AM. Immune system alterations by aldosterone during hypertension: from clinical observations to genomic and non-genomic mechanisms leading to vascular damage. Curr Mol Med. 2013;13:1035–46.

    Article  PubMed  Google Scholar 

  • Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol. 2013;9:86–98.

    Article  CAS  PubMed  Google Scholar 

  • New MI, Levine LS. Mineralocorticoid hypertension in childhood. Mayo Clin Proc. 1977;52:323–8.

    CAS  PubMed  Google Scholar 

  • New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab. 1977;44:924–33.

    Article  CAS  PubMed  Google Scholar 

  • O’Shaughnessy KM. Gordon syndrome: a continuing story. Pediatr Nephrol. 2015;30:1903–8.

    Article  PubMed  Google Scholar 

  • Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res. 2015;116:937–59.

    Article  CAS  PubMed  Google Scholar 

  • Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol. 1996;45:605–11.

    Article  CAS  Google Scholar 

  • Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13:263–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Picot CR, Perichon M, Lundberg KC, Friguet B, Szweda LI, Petropoulos I. Alterations in mitochondrial and cytosolic methionine sulfoxide reductase activity during cardiac ischemia and reperfusion. Exp Gerontol. 2006;41:663–7.

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    Article  CAS  PubMed  Google Scholar 

  • Pizzolo F, Friso S, Morandini F, et al. Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation. J Clin Endocrinol Metab. 2015;100:E1234–41.

    Article  PubMed  Google Scholar 

  • Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ. 2014;4:175–84.

    Article  PubMed  PubMed Central  Google Scholar 

  • Rezaei M, Andrieu T, Neuenschwander S, et al. Regulation of 11ß-hydroxysteroid dehydrogenase type 2 by microRNA. Hypertension. 2014;64:860–6.

    Article  CAS  PubMed  Google Scholar 

  • Romaine SP, Charchar FJ, Samani NJ, Tomaszewski M. Circulating microRNAs and hypertension – from new insights into blood pressure regulation to biomarkers of cardiovascular risk. Curr Opin Pharmacol. 2016;27:1–7.

    Article  CAS  PubMed  Google Scholar 

  • Romero DG, Plonczynski MW, Carvajal CA, Gomez-Sanchez EP, Gomez-Sanchez CE. Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology. 2008;149:2477–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension. 2006;48:232–8.

    Article  CAS  PubMed  Google Scholar 

  • Rudnicki M, Perco P, D Haene B, et al. Renal microRNA- and RNA-profiles in progressive chronic kidney disease. Eur J Clin Invest. 2016;46:213–26.

    Article  CAS  PubMed  Google Scholar 

  • Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51:432–9.

    Article  CAS  PubMed  Google Scholar 

  • Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes. 2007;31:864–70.

    Article  CAS  Google Scholar 

  • Scholl UI, Stolting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. eLife. 2015;4:e06315.

    Article  PubMed  PubMed Central  Google Scholar 

  • Scholl UI, Stolting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet. 2018;50:349–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schutten MT, Houben AJ, de Leeuw PW, Stehouwer CD. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology. 2017;32:197–209.

    Article  PubMed  Google Scholar 

  • Shackleton CH, Rodriguez J, Arteaga E, Lopez JM, Winter JS. Congenital 11beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol. 1985;22:701–12.

    Article  CAS  Google Scholar 

  • Shang Y, Yang X, Zhang R, Zou H, Zhao R. Low amino acids affect expression of 11β-HSD2 in BeWo cells through leptin-activated JAK-STAT and MAPK pathways. Amino Acids. 2012;42:1879–87.

    Article  CAS  PubMed  Google Scholar 

  • Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol. 2015;6:19.

    Article  PubMed  PubMed Central  Google Scholar 

  • Shi L, Liao J, Liu B, Zeng F, Zhang L. Mechanisms and therapeutic potential of microRNAs in hypertension. Drug Discov Today. 2015;20:1188–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shimkets RA, Warnock DG, Bositis CM, et al. Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407–14.

    Article  CAS  PubMed  Google Scholar 

  • Smolarek I, Wyszko E, Barciszewska AM, et al. Global DNA methylation changes in blood of patients with essential hypertension. Med Sci Monit. 2010;16:CR149–55.

    CAS  PubMed  Google Scholar 

  • Stehr CB, Carvajal CA, Lacourt P, et al. Marcadores de inflamación endotelial subclínica en una familia con hiperaldosteronismo familiar tipo I por mutación de novo. Rev Med Chil. 2008;136:1134–40.

    Article  CAS  PubMed  Google Scholar 

  • Stehr CB, Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens. 2010;28:2120–6.

    Article  CAS  PubMed  Google Scholar 

  • Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest. 1988;82:340–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100:1–10.

    Article  CAS  PubMed  Google Scholar 

  • Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol. 1992;19:319–22.

    Article  CAS  PubMed  Google Scholar 

  • Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab. 2000;85:3313–8.

    Article  CAS  PubMed  Google Scholar 

  • St-Pierre J, Fraser M, Vaillancourt C. Inhibition of placental 11beta-hydroxysteroid dehydrogenase type 2 by lead. Reprod Toxicol. 2016;65:133–8.

    Article  CAS  PubMed  Google Scholar 

  • Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004;32:e188.

    Article  PubMed  PubMed Central  Google Scholar 

  • Syed M, Ball JP, Mathis KW, et al. MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction. Am J Physiol Endocrinol Metab. 2018;315:E1154–E67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tapia-Castillo A, Carvajal CA, Campino C, et al. Polymorphisms in the RAC1 gene are associated with hypertension risk factors in a Chilean pediatric population. Am J Hypertens. 2014;27:299–307.

    Article  CAS  PubMed  Google Scholar 

  • Tapia-Castillo A, Carvajal CA, Campino C, et al. The expression of RAC1 and mineralocorticoid pathway-dependent genes are associated with different responses to salt intake. Am J Hypertens. 2015;28:722–8.

    Article  CAS  PubMed  Google Scholar 

  • Tapia-Castillo A, Carvajal CA, Allende F, Campino C, Fardella CE. Hypertensive patients that respond to aldosterone antagonists may have a nonclassical 11beta-HSD2 deficiency. Am J Hypertens. 2017;30:e6.

    Article  PubMed  Google Scholar 

  • Tapia-Castillo A, Baudrand R, Vaidya A, et al. Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome. J Clin Endocrinol Metab. 2019a;104:595–603.

    Article  PubMed  Google Scholar 

  • Tapia-Castillo A, Guanzon D, Palma C, et al. Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess. J Transl Med. 2019b;17:392.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tapia-Castillo A, Carvajal CA, Lopez-Cortes X, Vecchiola A, Fardella CE. Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess. Sci Rep. 2021;11:17156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 2008;18:404–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992;11:519–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Udali S, Guarini P, Moruzzi S, Choi SW, Friso S. Cardiovascular epigenetics: from DNA methylation to microRNAs. Mol Asp Med. 2013;34:883–901.

    Article  CAS  Google Scholar 

  • Ueda K, Nishimoto M, Hirohama D, et al. Renal dysfunction induced by kidney-specific gene deletion of Hsd11b2 as a primary cause of salt-dependent hypertension. Hypertension. 2017;70:111–8.

    Article  CAS  PubMed  Google Scholar 

  • Ulick S, Chan CK, Rao KN, Edassery J, Mantero F. A new form of the syndrome of apparent mineralocorticoid excess. J Steroid Biochem. 1989;32:209–12.

    Article  CAS  PubMed  Google Scholar 

  • Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069–75.

    Article  CAS  PubMed  Google Scholar 

  • Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39:1057–88.

    Article  PubMed  PubMed Central  Google Scholar 

  • Vitellius G, Delemer B, Caron P, et al. Impaired 11beta-hydroxysteroid dehydrogenase type 2 in glucocorticoid resistant patients. J Clin Endocrinol Metab. 2019;104:5205–16.

    Article  PubMed  Google Scholar 

  • Wang FE, Zhang C, Maminishkis A, et al. MicroRNA-204/211 alters epithelial physiology. FASEB J. 2010;24:1552–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang X, Wang HX, Li YL, et al. MicroRNA Let-7i negatively regulates cardiac inflammation and fibrosis. Hypertension. 2015;66:776–85.

    Article  CAS  PubMed  Google Scholar 

  • Watson B Jr, Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension. 1996;28:478–82.

    Article  CAS  PubMed  Google Scholar 

  • Wawrzyniak R, Mpanga AY, Struck-Lewicka W, et al. Untargeted metabolomics provides insight into the mechanisms underlying resistant hypertension. Curr Med Chem. 2019;26:232–43.

    Article  CAS  PubMed  Google Scholar 

  • White PC, Curnow KM, Pascoe L. Disorders of steroid 11beta-hydroxylase isozymes. Endocr Rev. 1994;15:421–38.

    CAS  PubMed  Google Scholar 

  • Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213–24.

    Article  CAS  PubMed  Google Scholar 

  • Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464–75.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wilson RC, Krozowski ZS, Li K, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263–6.

    CAS  PubMed  Google Scholar 

  • World Health Organization. Raised blood pressure. Geneva: World Health Organization; 2011. p. 39–40.

    Google Scholar 

  • Yau M, Haider S, Khattab A, et al. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11beta-hydroxysteroid dehydrogenase type 2 deficiency. Proc Natl Acad Sci U S A. 2017;114:E11248–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Young JWF, Calhoun DA, Lenders JWM, Stowasser M, Textor SC. Screening for endocrine hypertension: an Endocrine Society scientific statement. Endocr Rev. 2017;38:103–22.

    Article  Google Scholar 

  • Yu X, Odenthal M, Fries JW. Exosomes as miRNA carriers: formation-function-future. Int J Mol Sci. 2016;17:2028.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yu Z, Zhan X, Li X. MiR-204 inhibits hypertension by regulating proliferation and apoptosis of vascular smooth muscle cells. Int J Clin Exp Med. 2018;11:8214–22.

    CAS  Google Scholar 

  • Zhao H, Liu Y, Li Z, et al. Identification of essential hypertension biomarkers in human urine by non-targeted metabolomics based on UPLC-Q-TOF/MS. Clin Chim Acta. 2018;486:192–8.

    Article  CAS  PubMed  Google Scholar 

  • Zhou C, Ye F, Wu H, Ye H, Chen Q. Recent advances in the study of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) inhibitors. Environ Toxicol Pharmacol. 2017;52:47–53.

    Article  CAS  PubMed  Google Scholar 

  • Zhu X, Manning RD, Lu D, et al. Aldosterone stimulates superoxide production in macula densa cells. Am J Physiol Renal Physiol. 2011;301:F529–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu L, Ni C, Dong B, et al. A novel hedgehog inhibitor iG2 suppresses tumorigenesis by impairing self-renewal in human bladder cancer. Cancer Med. 2016;5:2579–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported partially by grants ANID-FONDECYT 1160695 (CEF), 1212006 (CAC) and 3200646 (ATC); CONICYT-FONDEQUIP EQM150023 (CAC); SOCHED 2019-09 (CAC) and CETREN-UC.

Author information

Authors and Affiliations

  1. Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

    Cristian A. Carvajal, Alejandra Tapia-Castillo, Thomas Uslar & Carlos E. Fardella

  2. Centro Traslacional de Endocrinología UC (CETREN), Santiago, Chile

    Cristian A. Carvajal, Alejandra Tapia-Castillo, Thomas Uslar & Carlos E. Fardella

Authors
  1. Cristian A. Carvajal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alejandra Tapia-Castillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Uslar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos E. Fardella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos E. Fardella .

Editor information

Editors and Affiliations

  1. Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, Rome, Italy

    Massimiliano Caprio

  2. Université Paris Cité, PARCC, Inserm, Paris, France

    Fabio Luiz Fernandes-Rosa

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Carvajal, C.A., Tapia-Castillo, A., Uslar, T., Fardella, C.E. (2023). Apparent Mineralocorticoid Excess. In: Caprio, M., Fernandes-Rosa, F.L. (eds) Hydro Saline Metabolism. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-27119-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-27119-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-27118-2

  • Online ISBN: 978-3-031-27119-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation